Fig. 2
From: ERK5 is activated by oncogenic BRAF and promotes melanoma growth
Silencing of ERK5 inhibits melanoma cell proliferation in vitro and in human melanoma xenografts. a, b Growth curves of A375 (a) and SSM2c (b) cells transduced with LV-shERK5 or LV-c lentiviruses. Data shown are mean ± SD of one representative experiment out of three performed in triplicates. **p < 0.01 as determined by Student's t-test. c Western blot shows ERK5 silencing efficiency (upper panel). Tubulin was used as loading control. Images of one representative experiment out of three performed with A375 cells transduced with the indicated lentiviruses stained with crystal violet after 10 days (lower panel). d, e In vivo tumor growth after subcutaneous injection of 1 × 104 A375 (d) or SSM2c (e) melanoma cells transduced with LV-c or LV-shERK5-1 lentiviruses. Data shown are mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 as determined by Student's t-test. f, g Representative images of A375 and SSM2c xenografts in athymic nude mice. Bar = 10 mm. h Table shows tumor take (number of tumors formed per number of injections) and latency (time from injection to tumor measurability) for each group. Data shown are mean ± SEM. i Western blot analysis of representative tumors derived from A375 and SSM2c xenografts. Actin was used as loading control
